Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data

Teitelbaum A, Ba-Mancini A, Huang H, Henk HJ

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23299776

DOI
10.1634/theoncologist.2012-0113

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Antineoplastic Agents /administration & dosage /economics; Boronic Acids /administration & dosage; Bortezomib; Female; Health Care Costs; Health Resources /economics; Hospitalization /economics; Humans; Male; Middle Aged; Multiple Myeloma /drug therapy /economics /epidemiology; Pyrazines /administration & dosage; Retrospective Studies; Thalidomide /administration & dosage /analogs & derivatives

AccessionNumber
22013008647

Date bibliographic record published
08/04/2013